SAS Output

23-FEB-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 0 0 0 0 0 BREAST
        9383 0 0 0 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 0 0 0 0 0  
      3 Endocrine Therapy Alone 2536 0 0 0 0 0  
        5083 0 0 0 0 0  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 925 175 90 42 17 3 BREAST
      2 Blinded drug + Endocrine 931 168 84 40 14 1  
        1856 343 174 82 31 4  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 10 6 5 3 3 1 SURV
      2 Randomization Non-surgical M 10 5 4 3 2 0  
      3 Patient Choice Surgery 56 19 8 2 2 1  
      4 Patient Choice Non-surgical M 100 6 0 0 0 0  
        176 36 17 8 7 2  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 658 255 118 63 21 4 CCD
      2 Site randomized: Control 485 208 115 64 22 6  
      3 SiteRand Int Risk: CSF 854 421 206 119 44 11  
      4 SiteRand Int Risk: No CSF 696 386 194 106 43 9  
        2693 1270 633 352 130 30  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 451 290 155 90 33 5 BREAST
        451 290 155 90 33 5  
 
  2 Y 2 Observation 193 125 65 38 16 5  
      3 MK-3475 (Pembrolizumab) 187 119 63 36 14 3  
        380 244 128 74 30 8  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 84 79 56 28 13 4 SURV
        84 79 56 28 13 4  
 
  2 Y 1 Carvedilol 15 13 9 5 3 1  
      2 No prophylaxis 16 14 11 5 3 0  
      3 Observation 45 44 32 15 8 1  
        76 71 52 25 14 2  
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition 1 Y   0 0 0 0 0 0 SXQOL
        0 0 0 0 0 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 80 55 30 17 6 1 GU
      2 Tokyo-172 BCG 79 55 31 16 5 0  
      3 Prime + Tokyo-172 BCG 78 55 31 16 5 2  
        237 165 92 49 16 3  
 
S1614-HBV in Ca Pts, TAF vs SOC 1 Y   0 0 0 0 0 0 SXQOL
        0 0 0 0 0 0  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y 0 Screening 26 26 26 20 13 1 CCD
        26 26 26 20 13 1  
 
  2 Y 1 Control (Usual Care) 1 1 1 0 0 0  
      2 Intervention (STMDDM) 1 1 1 0 0 0  
        2 2 2 0 0 0  
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 35 35 35 17 6 1 GU
        35 35 35 17 6 1  
 
  2 Y 1 Standard Systemic Therapy Only 5 5 5 2 1 0  
      2 SST + Surgery/RT 6 6 6 2 1 0  
        11 11 11 4 2 0  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 520 48 21 13 3 2 PREV
        520 48 21 13 3 2  
 
  1 Y 1 Blinded drug 81 25 13 8 2 1  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 79 20 8 5 1 0  
        231 45 21 13 3 1  
 

23-FEB-2019 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1600-Bladder,Radical Cystectomy Outcomes Nutrition regtype: 1
S1614-HBV in Ca Pts, TAF vs SOC regtype: 1